Microsoft Recommends Philips SpeechMike Premium Touch as the Successor to Nuance PowerMic
Article content
VIENNA — Speech Processing Solutions, global leader in professional dictation solutions under the Philips brand, today announced that the Philips SpeechMike Premium Touch has been officially recognized by Microsoft as the recommended successor to the soon-to-be-retired Nuance PowerMic series.
Article content
Article content
As the only microphone recommended by Microsoft for PowerMic replacement, the Philips SpeechMike Premium Touch delivers seamless, plug-and-play compatibility with many Nuance speech recognition solutions.
Article content
As the only microphone recommended by Microsoft for PowerMic replacement, the Philips SpeechMike Premium Touch delivers seamless, plug-and-play compatibility with many Nuance speech recognition solutions, including Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe offering medical, legal and business professionals a superior alternative for uninterrupted documentation workflows.
Article content
With an intuitive button layout mirroring the PowerMic, the Philips SpeechMike Premium Touch offers users a familiar, yet enhanced dictation experience to enable effortless transitions. Already in use by millions of medical, legal and business professionals worldwide, the Philips SpeechMike Premium Touch offers:
Article content
Compatibility with Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe, as well as other legacy software such as Dragon NaturallySpeaking, Dragon Medical Practice Edition, and Winscribe
Pre-configured Dragon function keys for convenient speech recognition control
Studio-quality microphone with noise reduction for unprecedented accuracy in speech recognition
Ergonomic design and hygienic housing, ideal for long-shift use and clinical work environments
Advanced touch sensor navigation replaces the need to switch to a mouse
Article content
'With the PowerMic now being retired in the coming weeks, organizations must move quickly to maintain continuity in documentation,' said Dr. Thomas Brauner, CEO at Speech Processing Solutions. 'The Philips SpeechMike Premium Touch is delivering both familiarity and unprecedented quality in speech recognition accuracy. I am delighted to be able to offer the Philips SpeechMike – the leading and most widely used dictation microphone in the world – to all existing PowerMic users.'
Article content
The Philips SpeechMike Premium Touch is available now through professional distribution channels.
Article content
Speech Processing Solutions (SPS) is the global leader in AI-powered dictation and transcription solutions. Active in over 50 countries with more than 4 million users and a network of 1,000+ partners, SPS develops award-winning speech-to-text technologies and devices under the Philips brand. Headquartered in Vienna, Austria, SPS is globally active with offices in Australia, Canada, Belgium, France, Germany, the UK, and the US.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
43 minutes ago
- Globe and Mail
Adobe vs. Apple: Which AI-Driven Tech Stock is a Better Buy Now?
Adobe ADBE and Apple AAPL are infusing artificial intelligence (AI) into their core offerings. While Adobe is incorporating AI into its creative products, Apple is adding Apple Intelligence to its core operating systems that power iPhone, iPad, Mac and Wearables. According to IDC, global spending on AI-supporting technologies will surpass $749 billion by 2028. IDC expects 67% of the projected $227 billion AI spending in 2025 will come from enterprises embedding AI capabilities into their core business operations. This bodes well for both Adobe and Apple stocks. However, both stocks are playing catch-up in the AI domain against the likes of Microsoft, Amazon and Alphabet. Shares of Adobe and Apple have suffered from challenging macroeconomic conditions and volatility related to higher tariffs. Year to date, Adobe shares have lost 13.9%, outperforming Apple's drop of 21.8%. Adobe and Apple Stock's Performance So, Adobe or Apple, which has an edge under the current scenario? The Case for Adobe Stock Adobe has expanded its AI portfolio with Adobe GenStudio and Firefly Services, which help brands and their agency partners collaborate on marketing campaigns. Adobe launched Firefly Video Model-powered Generative Extend in Premiere Pro, which leverages AI to instantly generate and expand the length of video and audio clips. Early in the fiscal second quarter, Adobe launched the new Firefly Image Model 4 for life-like images and the Firefly Image Model 4 Ultra for impeccable detail in complex visuals. Adobe Firefly is improving the potency of Creative Cloud desktop applications. The Firefly App is attracting users for AI-powered content ideation, creation and production, and its support for third-party models, including from Google, OpenAI and Black Forest Labs, is a key catalyst. First-time subscribers of the Firefly app grew 30% sequentially in the fiscal second quarter. Acrobat AI Assistant is unlocking new levels of productivity by cutting time to insights through conversational interfaces. Adobe Express is using AI to enable consumers to quickly design and publish engaging content through conversational AI in an easy-to-use, all-in-one application. Adobe is integrating these solutions to facilitate a smoother creation-to-consumption process across mobile apps, web browsers and desktop offerings. Adobe's monthly active users across these categories surpassed more than 700 million users at the end of the second quarter of fiscal 2025. Adobe's AI book of business from AI-first products, including Acrobat AI assistant, Firefly App and Services and GenStudio for Performance Marketing, is tracking ahead of the $250 million ending Annual Recurring Revenue (ARR) target by the end of fiscal 2025. The company exited the fiscal second quarter with Digital Media ARR of $18.09 billion, up 12% year over year. The Case for Apple Stock Apple is seeing better iPhone 16 sales in regions where Apple Intelligence is available. Apple expanded the availability of Apple Intelligence with iOS 18.4, iPadOS 18.4, and macOS Sequoia 15.4 updates in new languages, including French, German, Italian, Portuguese (Brazil), Spanish, Japanese, Korean, and Chinese (simplified) — as well as localized English for Singapore and India — and are accessible in nearly all regions around the world. At the end of 2025, Apple Intelligence will be available in eight more languages: Danish, Dutch, Norwegian, Portuguese, Swedish, Turkish, Chinese (traditional) and Vietnamese. At this year's annual Worldwide Developers Conference, the company announced new Apple Intelligence features like Live Translation, updates to visual intelligence, as well as enhancements to Image Playground and Genmoji. Shortcuts can access Apple Intelligence directly. Developers also get access to the on-device large language model, which is at the core of Apple Intelligence. The latest features are now available for testing and are expected to be generally available this fall with supported devices. Apple Intelligence is now getting added to Apple Wallet, and users can make purchases with Apple Pay. Powered by Apple Intelligence, Apple Wallet can now automatically identify, summarize and display order tracking details from emails sent from merchants or delivery carriers. Meanwhile, Apple Pay expands the ability to pay with rewards and installments to in-store purchases for added flexibility and choice. Adobe Earnings Estimate Revision Positive, AAPL's Goes South The Zacks Consensus Estimate for Adobe's fiscal 2025 earnings is pegged at $20.41 per share, up 5 cents over the past 30 days, indicating a 10.8% increase over 2024's reported figure. The consensus mark for Apple's fiscal 2025 earnings has declined by a penny to $7.11 per share over the past 30 days, suggesting 5.33% growth over fiscal 2024. Valuation: Adobe is Cheaper Than Apple Both Apple and Adobe are overvalued, as suggested by the Value Score of D. In terms of forward 12-month Price/Sales, Adobe shares are trading at 6.62X, lower than Apple's 7.04X. AAPL and ADBE Valuation Here's Why Adobe is a Better Buy Than Apple Apple is expected to suffer from the underwhelming performance of Apple Intelligence and a delay in launch in important markets like Mainland China. Higher tariffs negatively impact Apple's China supply chain. Tariffs are currently expected to have a negative impact of roughly $900 million in the third quarter of fiscal 2025. Meanwhile, Adobe's growing focus on improving monetization from Firefly and GenStudio is noteworthy. GenStudio for Performance Marketing is empowering teams to create their own on-brand content, supporting ad creation and activation for Google, LinkedIn, Meta, Microsoft, Snap and TikTok. In the customer experience domain, Adobe is gaining prominence with Amazon, Microsoft, SAP and ServiceNow choosing it as their preferred partner. These factors are expected to drive top-line growth for Adobe, which is now expected between $23.5 billion and $23.6 billion (up from previous guidance between $23.30 billion and $23.55 billion). Currently, Adobe has a Zacks Rank #2 (Buy), making the stock a stronger pick compared with Apple, which has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
Will the Traction in SASE and Zero Trust Keep Driving Cloudflare?
Cloudflare NET signed its longest secure access service edge (SASE) contract in the first quarter of 2025 and has been gaining traction constantly as enterprises modernize and simplify their network security and connectivity. Cloudflare combines its Zero Trust security products like Cloudflare Gateway, remote browser isolation and cloud access security broker with its Network Services like Magic WAN, Magic Transit and Magic Firewall, Cloudflare Network Interconnect and spectrum to provide an end-to-end cloud-based secured SASE solution that simplifies the adoption process for its clients, helping NET in winning larger deals. Cloudflare has also partnered with industry giants like TD SYNNEX to expand the geographical reach of its managed security services across Latin America, including Zero Trust and SASE solutions, to support MSSP growth in the region. In the Zero Trust space, NET has been witnessing tremendous customer growth for its core application services portfolio, Zero Trust solutions and network services like Magic Transit in Cloudflare One. NET has made Zero Trust integrations with companies like Atlassian, Microsoft and Sumo Logic, to enable small, medium and large-sized businesses to secure reliable tools and applications with enterprise-ready Zero Trust security. This strategy has expanded the reach of the Cloudflare One Zero Trust platform to more than 10,000 companies worldwide. These factors have helped Cloudflare to achieve 250,819 paying customers at the end of the first quarter, up 27% year over year. NET added 30 new customers during the quarter who contributed more than $100,000 in annual revenues. The total count of such customers reached 3,527 at the end of the quarter. How Competitors Fare Against Cloudflare Cloudflare faces stiff competition from Palo Alto Networks PANW and Zscaler ZS in SASE and Zero Trust offerings. Palo Alto Networks' SASE platform has an active customer user base of more than 6,000. Palo Alto Networks achieved 36% year-over-year growth in SASE ARR and 16% growth in $1 million-plus deals in the third quarter of fiscal 2025, making it a dominant SASE player. Zscaler, on the other hand, leads the Zero Trust space and also offers SASE solutions. The company offers Zero Trust Network Access solutions through Zscaler Private Access, which enables secure application access without VPN. ZS is now moving toward the Zero Trust Everywhere model, which secures cloud, endpoint and network. Zscaler also provides a full SASE platform by combining identity access, private access and cloud protection. Since the competition in the SASE and Zero Trust space is high, this remains an investor's concern for Cloudflare's growth. However, since the SASE market is witnessing a CAGR of 23.6% and the Zero Trust Market is seeing a CAGR of 16.7%, Cloudflare has enough headroom to expand its business. Cloudflare's Price Performance, Valuation and Estimates Shares of NET have surged 68.6% year to date compared with the Zacks Internet - Software industry's growth of 13%. From a valuation standpoint, NET trades at a forward price-to-sales ratio of 26.77X, higher than the industry's average of 5.68X. The Zacks Consensus Estimate for NET's fiscal 2025 and 2026 earnings implies year-over-year growth of 5.33% and 31.64%, respectively. The estimates for fiscal 2025 earnings have been revised downward in the past 60 days, and the 2026 earnings have been revised downward in the past 30 days. NET currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report Zscaler, Inc. (ZS): Free Stock Analysis Report Cloudflare, Inc. (NET): Free Stock Analysis Report
Globe and Mail
5 hours ago
- Globe and Mail
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the Vaccines unit, generic competition for some drugs and broader economic pressure. Let's discuss these factors in detail to understand how to play GSK's stock amid the recent price increase. GSK Specialty Medicines Unit on a Strong Footing GSK is witnessing increased sales growth of its Specialty Medicines unit, particularly reflecting successful new launches in Oncology and long-acting HIV medicines. Sales are rising in all areas, HIV, Immunology/Respiratory as well as Oncology. Sales of the Specialty Medicines unit rose 19% in 2024, driven by double-digit growth in all therapy areas. The positive trend continues in 2025 with sales rising 17% in the first quarter of 2025. In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient demand and contributing to top-line growth. In 2025, the company expects sales in the Specialty Medicines segment to rise in a low double-digit percentage at CER, despite the impact from the Inflation Reduction Act or IRA. Specialty Medicines, which now accounts for around 40% of GSK's sales, is expected to be more than 50% of GSK's total revenue by 2031. GSK's Promising Pipeline GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. GSK's pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection ('UTI') were approved in the United States in the first quarter of 2025. Its blockbuster drug Nucala was approved for treating chronic obstructive pulmonary disease or COPD, its fifth indication, in May 2025. Regulatory applications seeking approval of the Blenrep combination for relapsed/refractory multiple myeloma and depemokimab for two indications (chronic rhinosinusitis with nasal polyps or CRSwNP and asthma with type II inflammation) are under review in the United States and some other countries. FDA decisions on all these filings are expected in 2025. Blenrep combinations were approved in the United Kingdom and Japan in April/May 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and Nucala for COPD are already approved in the United States. GSK's Vaccine Sales Slowing Down GSK's first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix. U.S. sales of Shingrix declined 21% in the first quarter of 2025 due to lower demand as a result of challenges in activating harder-to-reach consumers. Arexvy's global sales declined 57% in the first quarter. Revised recommendations for RSV vaccinations issued in June 2024 by the U.S. Advisory Committee on Immunization Practices (ACIP) have been hurting sales of Arexvy from the second half of 2024 in the United States. In June, the ACIP recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. A challenging macro environment in China and potential for changes in vaccination policies in the United States are expected to hurt Vaccine sales in the near term. In 2025, the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK's Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since May. GSK Stock Outperforms Industry, Sector and S&P GSK's stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.63 on a forward 12-month basis, lower than 15.63 for the industry. The stock also trades below its 5-year mean of 10.25. The stock is much cheaper than several other large drugmakers like Eli Lilly LLY, Novo Nordisk NVO, AbbVie ABBV and AstraZeneca. GSK Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $4.26 to $4.42 per share for 2025 and from $4.71 to $4.82 per share for 2026 over the past 60 days. GSK's Estimates Stay Invested in GSK Stock GSK has its share of problems. Competitive pressure on HIV and respiratory drugs has risen. The dolutegravir HIV franchise patent expires in the 2028-2029 period, and U.S. vaccine sales are slowing down. In 2025, GSK also expects a negative sales impact of £400-500 million due to the impact of the IRA Medicare Part D redesign. However, the company is consistently growing its sales and profits, mainly driven by its Specialty Medicines segment. For the five-year period till 2026, GSK expects to record more than 7% sales growth while core operating profit is expected to increase more than 11% on a CAGR basis. In this period, Specialty Medicines is expected to rise in the low-to-mid teens percentage while General Medicines is expected to rise by a low single-digit percentage. The growth in Specialty Medicines and improvement in General Medicines are making up for a slowdown in the Vaccines unit. The company also resolved the vast majority of Zantac litigations in 2024, which had long been an overhang on the stock. GSK believes it is well-positioned to navigate and mitigate the potential financial impact of tariffs on pharmaceutical imports through supply chain and increased productivity initiatives We suggest investors who own this Zacks Rank #3 (Hold) stock stay invested for now, considering steady sales and profit improvement in the coming years. Consistently rising estimates also reflect analysts' optimistic outlook for future growth in profits. Buying the stock at its present cheap valuation can prove prudent for long-term investors who are interested in buying blue-chip companies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
